Search results
Results from the WOW.Com Content Network
Olanzapine occupancy at 5-HT 2A receptor are high at all doses (5 mg to 20 mg). It is reported that 5 mg dose of olanzapine produced a mean occupancy of 85% at 5 mg, 88% at 10 mg, and 93% at 20 mg dose . [95] Olanzapine had the highest affinity of any second-generation antipsychotic towards the P-glycoprotein in one in vitro study. [96]
Olanzapine/fluoxetine (trade name Symbyax, created by Eli Lilly and Company) is a fixed-dose combination medication containing olanzapine (Zyprexa), an atypical antipsychotic, and fluoxetine (Prozac), a selective serotonin reuptake inhibitor (SSRI).
Another method is "defined daily dose" (DDD), which is the assumed average dose of an antipsychotic that an adult would receive during long-term treatment. [15] DDD is primarily used for comparing the utilization of antipsychotics (e.g. in an insurance claim database), rather than comparing therapeutic effects between antipsychotics. [15]
Very common adverse effects of olanzapine, occurring more than 10%, include: Weight gain (dose-dependent). Weight gain of over 7% of a person's initial body weight prior to treatment is in this category of very common too with some estimates of its incidence putting it at around 40.6%.
Zyprexa that has expanded Zyprexa's reach into this community of prescribers. Lilly is actively pursuing a claim for Zyprexa in the psychosis associated with Alzheimer's Disease and our market intelligence indicates they may be up to 6 or more months ahead of our tlmelines. Seroquel has been also been aggressive in the elderly market.
The plan targeted $1.059 billion in U.S. sales for 2000, through 707,000 in-person sales calls to doctors who would prescribe 452 million pills or oral doses, priced at about $2.50 per dose. Total costs—including $51 million for “public relations, grants, sales support and medical education programs,” and $14.3 million for free samples ...
Olanzapine/samidorphan, sold under the brand name Lybalvi, is a fixed-dose combination medication for the treatment of schizophrenia and bipolar I disorder. [1] It contains olanzapine , an atypical antipsychotic , and samidorphan , an opioid antagonist .
The consensus is to reduce dosage gradually over several weeks, e.g. 4 or more weeks for diazepam doses over 30 mg/day, [1] with the rate determined by the person's ability to tolerate symptoms. [120] The recommended reduction rates range from 50% of the initial dose every week or so, [121] to 10–25% of the daily dose every 2 weeks. [120]